InvestorsHub Logo
Followers 30
Posts 2559
Boards Moderated 0
Alias Born 04/01/2009

Re: 308er post# 478

Thursday, 11/29/2018 2:20:30 PM

Thursday, November 29, 2018 2:20:30 PM

Post# of 897
According to what I understand from BioVie:

Mallinckrodt is targeting hospitalized patients with Type 1 HRS (meaning the onset of renal and multi-organ failure) with an expected 2 to 4 week median survival. BioVie is targeting ambulatory ascites patients (sometime overlapping with Type 2 HRS) who are severely ill and at risk of progressing to hospitalization with HRS-1. BioVie is trying to prevent them from progressing to Type 1 HRS.

DISCLAIMER: All I say is just IMHO and does not constitute investment advice. My wife informs me frequently that I know nothing. I say you should trust no one on the internet.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BIVI News